JP Morgan initiated coverage on Zealand Pharma with an overweight rating and a target price of 1,100 Danish kroner, signaling confidence in the company’s growth potential. On the other hand, Pareto Securities started coverage on Logistea with a buy rating and a target price of 20 kronor, indicating optimism in the company’s prospects.
In a contrasting move, Pareto Securities lowered the target price for Torm to 197 Danish kroner from 210, maintaining a hold rating. This adjustment reflects the changing landscape within the industry and the company’s performance. Similarly, Pareto Securities decreased the target price for Mentice to 28 kronor from 36, while maintaining a hold rating, showcasing their assessment of the company’s outlook.
On a positive note, Pareto Securities raised the target price for Lundin Mining to 185 kronor from 175, reiterating a buy rating. This upward revision underscores their bullish stance on the company’s future growth. However, Pareto Securities reduced the target price for REC Silicon to 5 Norwegian kroner from 8, maintaining a hold rating, reflecting their cautious outlook on the company’s performance.
Meanwhile, Carnegie lowered the target price for Rugvista to 60 kronor from 65, while reiterating a buy rating, indicating a shift in their evaluation of the company. Additionally, SEB raised the target price for Storskogen to 13 kronor from 12, maintaining a buy rating, signaling confidence in the company’s trajectory.
In a different development, Carnegie cut the target price for Oncopeptides to 1.70 kronor from 2.50, while maintaining a hold rating, reflecting their revised assessment of the company’s future prospects. Similarly, JP Morgan reduced the target price for GN Store Nord to 252 Danish kroner from 266, while reiterating an overweight rating, suggesting a reevaluation of the company’s performance.
BNP Paribas Exane raised the target price for Novonesis to 364 Danish kroner from 360, while maintaining an underperform rating, highlighting their adjusted outlook on the company’s potential. Sparebank 1 Markets increased the target price for Hexagon Composites to 65 Norwegian kroner from 45, reiterating a buy rating, indicating their positive view on the company’s growth prospects.
DNB raised the target price for Hexagon Composites to 54 Norwegian kroner from 50, maintaining a buy rating, showcasing their confidence in the company’s future performance. Arctic decreased the target price for FLEX LNG to 291 Norwegian kroner from 325, while reiterating a buy rating, reflecting their revised assessment of the company’s trajectory.
Furthermore, DNB reduced the target price for Borr Drilling to 65 Norwegian kroner from 95, maintaining a buy rating, signaling a shift in their evaluation of the company’s outlook. Carnegie raised the target price for Autostore to 17 Norwegian kroner from 16, reiterating a buy rating, demonstrating their positive stance on the company’s future growth potential.
In contrast, Sparebank 1 Markets decreased the target price for REC Silicon to 3 Norwegian kroner from 6.50, maintaining a sell rating, reflecting their cautious outlook on the company’s performance. SEB raised the target price for Norconsult to 44 Norwegian kroner from 43, maintaining a buy rating, indicating their optimism in the company’s future prospects.
Additionally, SEB increased the target price for Multiconsult to 220 Norwegian kroner from 215, reiterating a buy rating, showcasing their positive view on the company’s growth potential. Pareto Securities lowered Kambi to hold from buy, with a target price of 117 kronor from 135, reflecting their revised assessment of the company’s future performance.
Moreover, Pareto Securities reduced the target price for Salmon Evolution to 9 Norwegian kroner from 9.50, while maintaining a buy rating, indicating their adjusted outlook on the company’s trajectory. Fearnley decreased the target price for Torm to 185 Danish kroner from 236, maintaining a hold rating, reflecting their revised evaluation of the company’s future prospects.
DZ Bank lowered the target price for Novo Nordisk to 772 Danish kroner from 855, maintaining a hold rating, showcasing their revised outlook on the company’s performance. Goldman Sachs reduced the target price for Zealand Pharma to 1,095 Danish kroner from 1,106, while reiterating a buy rating, indicating a reevaluation of the company’s growth potential.
Carnegie increased the target price for Truecaller to 79 kronor from 75, maintaining a buy rating, demonstrating their positive stance on the company’s future growth. Barclays decreased the target price for GN Store Nord to 178 Danish kroner from 180, maintaining a neutral rating, highlighting their adjusted assessment of the company’s performance.